Covidien — Merger or Acquisition (November 2012)
16 slides from Covidien's merger presentation, Nov 26, 2012
Slide 1: Spin-off of Pharmaceuticals
Spin-off of Pharmaceuticals November 26, 2012 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements November 26, 2012 2 | This presentation contains certain “forward-looking statements” that are not historical facts. These statements are based on management’s current expectations and are subject to risks, uncertainty and changes in circumstances, which may cause actual r
Slide 3: Forward-Looking Statements (con't)
Forward-Looking Statements (con’t) – Other business effects, including the effects of industry, economic or political conditions outside of Covidien’s control – Transaction costs and other risks and uncertainties discussed in Covidien’s filings with the U.S. Securities and Exchange Commission, inclu
Slide 4: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation discusses measures which may be considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to and not a substitute for financial
Slide 5: Basis of "New Covidien" references
References to “New Covidien” in this presentation reflect the Covidien plc historical reported GAAP results less the historical reported GAAP results of the Pharmaceuticals segment. These results are not necessarily representative of the results that will be reported by “New Covidien” or the Pharmac
Slide 6: 2012 Net Sales by Segment
Medical Supplies 2012 Net Sales Medical Devices Pharma- ceuticals 68% $8.1B 15% $1.8B 17% $2.0B 82% $8.1B 18% $1.8B Active Pharmaceutical Ingredients Contrast Products Specialty Pharmaceuticals Radiopharmaceuticals 28% 27% 23% 22% Covidien $11.9B “New Covidien” $9.9B Pharmaceuticals $2.0B $573MM $54
Slide 7: Product Portfolio – Covidien
Product Portfolio – Covidien Endomechanical 19.7% Soft Tissue Repair 7.4% Energy 11.0% Oximetry & Monitoring 7.3% Airway & Ventilation 6.3% Vascular 13.5% Other Medical Devices 3.2% Specialty Pharmaceuticals 4.8% Active Pharmaceutical Ingredients 3.7% Contrast Products 4.6% Radiopharmaceuticals 3.8%
Slide 8: Product Portfolio – "New Covidien"
Endomechanical 23.7% Soft Tissue Repair 9.0% Energy 13.2% Oximetry & Monitoring 8.8% Airway & Ventilation 7.5% Vascular 16.3% Other Medical Devices 3.8% Nursing Care 8.2% Medical Surgical 4.5% SharpSafety 2.9% OEM 2.1% Medical Devices 82.3% Medical Supplies 17.7% * Based on 2011 sales Product Portfo
Slide 9: 2012 Net Sales by Geography
United States Europe* Other Americas 2012 Net Sales by Geography ($ billions) Asia- Pacific 6% $0.7 55% $6.6 16% $1.9 22% $2.7 Covidien $11.9 6% $0.6 53% $5.2 18% $1.8 23% $2.3 “New Covidien” $9.9 Pharmaceuticals $2.0 6% $0.1 67% $1.4 6% $0.1 21% $0.4 * Includes Europe, Middle East and Africa Novemb
Slide 10: Historical Sales Growth
Historical Sales Growth ($ billions) 2012 2007-2012 Net Sales* CAGR Medical Devices $8.1 9.2% Pharmaceuticals 2.0 0.4% Medical Supplies 1.8 0.3% Total Covidien $11.9 5.9% “New Covidien” $9.9 7.3% Pharmaceuticals 2.0 0.4% * As reported November 26, 2012 10 |
Slide 11: 2012 Adjusted Gross Margin, R&D, Depreciation & Amortization
2012 Adjusted Gross Margin, R&D, Depreciation & Amortization ($ millions) Adjusted Adjusted Net Sales Gross Profit* Gross Margin* Covidien $11,852 $6,859 57.9% “New Covidien” $9,851 $5,947 60.4% Pharmaceuticals $2,001 $912 45.6% R&D % of Depreciation & Net Sales Amortization Covidien 5.3% $633 “New
Slide 12: 2012 Segment Operating Income and Margin
2012 Segment Operating Income and Margin* ($ millions) % of Operating Income Net Sales Medical Devices $2,499 30.8% Pharmaceuticals 337 16.8% Medical Supplies 214 12.3% Reportable Segments 3,050 25.7% Less Pharmaceuticals (337) “New Covidien” $2,713 27.5% November 26, 2012 12 |
Slide 13: 2012 Segment Operating Income and Margin
2012 Segment Operating Income and Margin* ($ millions) Covidien “New Covidien” November 26, 2012 13 |
Slide 14: Manufacturing Footprint
Manufacturing Footprint Covidien 51 Manufacturing facilities in 18 countries Pharmaceuticals 10 Manufacturing facilities in 4 countries “New Covidien” 41 Manufacturing facilities in 17 countries November 26, 2012 14 |
Slide 15: Reconciliation
Reconciliation ($ millions) Gross margin Covidien plc 2012 percent GAAP gross profit $6,814 57.5% Impairments 15 Restructuring and related charges, net* 13 Transaction costs* 17 Adjusted gross profit $6,859 57.9% November 26, 2012 15 | * Restructuring includes restructuring-related accelerated depre
Slide 16: Spin-off of Pharmaceuticals
Spin-off of Pharmaceuticals November 26, 2012